Vironexis Announces Complete and Durable Responses in Relapsed/Refractory ALL Patients Treated with VNX-101

Data ReadoutpositiveVNX-101Positive

AI Analysis

Summary

Vironexis announced complete and durable responses in relapsed/refractory acute lymphoblastic leukemia (ALL) patients treated with VNX-101. The positive clinical data represents meaningful progress in a difficult-to-treat patient population.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Complete and durable responses in relapsed/refractory ALL patients

Importance:6/10

Sentiment:

0.75

oncologyhematologyALLrelapsed/refractoryclinical trial

Read the original article

Published by GlobeNewswire Clinical Studies on September 21, 2026 11:00 AM

Read Original